| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
0 |
| Employees |
43 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-83 |
| Cash Flow (TTM) (Millions $) |
-13 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Athersys Inc is a biotechnology company founded in 1995 and based in Cleveland, Ohio. The company specializes in developing regenerative medicine therapies, focusing on a novel stem cell platform called MultiStem. Athersys is primarily focused on developing treatments for conditions such as ischemic stroke, acute respiratory distress syndrome, and trauma.
The MultiStem platform involves the discovery and development of adult-derived off-the-shelf stem cell therapies. These therapies can be administered to patients without the need for matching or immune suppression, which makes them more accessible and potentially easier to implement in clinical settings.
Athersys has conducted numerous preclinical and clinical trials to evaluate the safety and effectiveness of its regenerative medicine therapies. The company has collaborations with various academic institutions, government agencies, and industry partners to further research and development efforts.
The company's key product candidates include MultiStem for treating ischemic stroke, acute myocardial infarction, and inflammatory bowel disease. Athersys has also explored the application of MultiStem in treating COVID-19-related lung injury.
Athersys Inc is driven by a mission to develop innovative therapies to improve patient outcomes and address significant unmet medical needs. The company continues to pursue research, clinical trials, and partnerships to advance its regenerative medicine pipeline and bring potential treatments to market.
Company Address: 3201 Carnegie Avenue Cleveland 44115 OH
Company Phone Number: 431-9900 Stock Exchange / Ticker: ATHX
|
%
0.2%